Matches in SemOpenAlex for { <https://semopenalex.org/work/W4321438787> ?p ?o ?g. }
- W4321438787 endingPage "1018" @default.
- W4321438787 startingPage "1008" @default.
- W4321438787 abstract "Purpose In this multicenter collaboration, we report real-world data in the largest published series of long-term outcomes for patients with relapsed/refractory (r/r) Hodgkin lymphoma (HL) treated with peritransplant radiation therapy (pt-RT) and high-dose chemotherapy with autologous stem cell transplant (ASCT). Methods and Materials We conducted a retrospective analysis including data from 12 institutions. Eligibility required histologic diagnosis of HL, receipt of ASCT plus pt-RT between 2004 and 2014 for r/r HL, and age ≥18 years at the time of ASCT. All patients received salvage chemotherapy for maximum debulking before ASCT. Metabolic responses were scored according to the Lugano Classification. The primary endpoint was overall survival (OS). Univariate and multivariate Cox proportional hazards were calculated to estimate the effect of covariates on patients’ outcome. Results One hundred thirty-one patients were eligible: 68 were male (52%), and median age at ASCT was 32 years (range, 18-70). At the time of diagnosis with r/r HL, 92 patients (70%) had limited (stage I-II) disease, and 10 patients (8%) had bulky disease. Pt-RT was given pre-ASCT in 32 patients (24%) and post-ASCT in 99 (76%); median prescribed dose was 30.6 Gy (range, 20-44 Gy). With median follow-up of 60 months, 3- and 5-year OS were 84% and 77%, while 3- and 5-year progression-free survival were 75% and 72%, respectively. On univariate and multivariate analysis, advanced stage at relapse (hazard ratio [HR], 2.18; P = .04), irradiation of >3 sites (HR, 3.69; P = .01), and incomplete metabolic response after salvage chemotherapy (HR, 2.24; P = .01) had a negative effect on OS. The sequencing of pt-RT (pre- vs post-ASCT) did not affect outcomes. Conclusions Overall, the addition of pt-RT to ASCT for patients with r/r HL is associated with very good outcomes. Limited relapsed disease with ≤3 sites involved and achievement of complete metabolic response after salvage chemotherapy were predictive of more favorable prognosis. In this multicenter collaboration, we report real-world data in the largest published series of long-term outcomes for patients with relapsed/refractory (r/r) Hodgkin lymphoma (HL) treated with peritransplant radiation therapy (pt-RT) and high-dose chemotherapy with autologous stem cell transplant (ASCT). We conducted a retrospective analysis including data from 12 institutions. Eligibility required histologic diagnosis of HL, receipt of ASCT plus pt-RT between 2004 and 2014 for r/r HL, and age ≥18 years at the time of ASCT. All patients received salvage chemotherapy for maximum debulking before ASCT. Metabolic responses were scored according to the Lugano Classification. The primary endpoint was overall survival (OS). Univariate and multivariate Cox proportional hazards were calculated to estimate the effect of covariates on patients’ outcome. One hundred thirty-one patients were eligible: 68 were male (52%), and median age at ASCT was 32 years (range, 18-70). At the time of diagnosis with r/r HL, 92 patients (70%) had limited (stage I-II) disease, and 10 patients (8%) had bulky disease. Pt-RT was given pre-ASCT in 32 patients (24%) and post-ASCT in 99 (76%); median prescribed dose was 30.6 Gy (range, 20-44 Gy). With median follow-up of 60 months, 3- and 5-year OS were 84% and 77%, while 3- and 5-year progression-free survival were 75% and 72%, respectively. On univariate and multivariate analysis, advanced stage at relapse (hazard ratio [HR], 2.18; P = .04), irradiation of >3 sites (HR, 3.69; P = .01), and incomplete metabolic response after salvage chemotherapy (HR, 2.24; P = .01) had a negative effect on OS. The sequencing of pt-RT (pre- vs post-ASCT) did not affect outcomes. Overall, the addition of pt-RT to ASCT for patients with r/r HL is associated with very good outcomes. Limited relapsed disease with ≤3 sites involved and achievement of complete metabolic response after salvage chemotherapy were predictive of more favorable prognosis." @default.
- W4321438787 created "2023-02-22" @default.
- W4321438787 creator A5004642255 @default.
- W4321438787 creator A5011319426 @default.
- W4321438787 creator A5011697206 @default.
- W4321438787 creator A5013108855 @default.
- W4321438787 creator A5014172365 @default.
- W4321438787 creator A5026320968 @default.
- W4321438787 creator A5031344401 @default.
- W4321438787 creator A5046683922 @default.
- W4321438787 creator A5046704362 @default.
- W4321438787 creator A5052878762 @default.
- W4321438787 creator A5055602344 @default.
- W4321438787 creator A5060509370 @default.
- W4321438787 creator A5062533736 @default.
- W4321438787 creator A5072297631 @default.
- W4321438787 creator A5075768248 @default.
- W4321438787 creator A5077636165 @default.
- W4321438787 creator A5079557357 @default.
- W4321438787 creator A5084878272 @default.
- W4321438787 date "2023-08-01" @default.
- W4321438787 modified "2023-09-25" @default.
- W4321438787 title "Peritransplant Radiation Therapy in Patients With Refractory or Relapsed Hodgkin Lymphoma Undergoing Autologous Stem Cell Transplant: Long-Term Results of a Retrospective Study of the Fondazione Italiana Linfomi" @default.
- W4321438787 cites W1993091132 @default.
- W4321438787 cites W1997194652 @default.
- W4321438787 cites W2001744336 @default.
- W4321438787 cites W2006178875 @default.
- W4321438787 cites W2026188656 @default.
- W4321438787 cites W2032132558 @default.
- W4321438787 cites W2047340233 @default.
- W4321438787 cites W2062486240 @default.
- W4321438787 cites W2080313054 @default.
- W4321438787 cites W2111070506 @default.
- W4321438787 cites W2112065237 @default.
- W4321438787 cites W2115707980 @default.
- W4321438787 cites W2119147717 @default.
- W4321438787 cites W2122654415 @default.
- W4321438787 cites W2145917992 @default.
- W4321438787 cites W2157717016 @default.
- W4321438787 cites W2163369762 @default.
- W4321438787 cites W2274888609 @default.
- W4321438787 cites W2518688062 @default.
- W4321438787 cites W2563933574 @default.
- W4321438787 cites W2584333717 @default.
- W4321438787 cites W2596050027 @default.
- W4321438787 cites W2616864458 @default.
- W4321438787 cites W2753271606 @default.
- W4321438787 cites W2783028863 @default.
- W4321438787 cites W2807245422 @default.
- W4321438787 cites W2905413135 @default.
- W4321438787 cites W2976722339 @default.
- W4321438787 cites W2985991947 @default.
- W4321438787 cites W2994368505 @default.
- W4321438787 cites W3012488014 @default.
- W4321438787 cites W3015294681 @default.
- W4321438787 cites W3132415718 @default.
- W4321438787 cites W3169462609 @default.
- W4321438787 cites W3203743689 @default.
- W4321438787 cites W3205530939 @default.
- W4321438787 cites W4225313554 @default.
- W4321438787 cites W4310117867 @default.
- W4321438787 doi "https://doi.org/10.1016/j.ijrobp.2023.02.019" @default.
- W4321438787 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36822373" @default.
- W4321438787 hasPublicationYear "2023" @default.
- W4321438787 type Work @default.
- W4321438787 citedByCount "0" @default.
- W4321438787 crossrefType "journal-article" @default.
- W4321438787 hasAuthorship W4321438787A5004642255 @default.
- W4321438787 hasAuthorship W4321438787A5011319426 @default.
- W4321438787 hasAuthorship W4321438787A5011697206 @default.
- W4321438787 hasAuthorship W4321438787A5013108855 @default.
- W4321438787 hasAuthorship W4321438787A5014172365 @default.
- W4321438787 hasAuthorship W4321438787A5026320968 @default.
- W4321438787 hasAuthorship W4321438787A5031344401 @default.
- W4321438787 hasAuthorship W4321438787A5046683922 @default.
- W4321438787 hasAuthorship W4321438787A5046704362 @default.
- W4321438787 hasAuthorship W4321438787A5052878762 @default.
- W4321438787 hasAuthorship W4321438787A5055602344 @default.
- W4321438787 hasAuthorship W4321438787A5060509370 @default.
- W4321438787 hasAuthorship W4321438787A5062533736 @default.
- W4321438787 hasAuthorship W4321438787A5072297631 @default.
- W4321438787 hasAuthorship W4321438787A5075768248 @default.
- W4321438787 hasAuthorship W4321438787A5077636165 @default.
- W4321438787 hasAuthorship W4321438787A5079557357 @default.
- W4321438787 hasAuthorship W4321438787A5084878272 @default.
- W4321438787 hasConcept C121608353 @default.
- W4321438787 hasConcept C126322002 @default.
- W4321438787 hasConcept C141071460 @default.
- W4321438787 hasConcept C143998085 @default.
- W4321438787 hasConcept C144301174 @default.
- W4321438787 hasConcept C167135981 @default.
- W4321438787 hasConcept C207103383 @default.
- W4321438787 hasConcept C2776694085 @default.
- W4321438787 hasConcept C2779050716 @default.
- W4321438787 hasConcept C2779338263 @default.
- W4321438787 hasConcept C2780427987 @default.
- W4321438787 hasConcept C2780775027 @default.
- W4321438787 hasConcept C2781100745 @default.